A Vine-Tea Flavonoid with a Long Research History
A compound recorded in the pharmacopoeia of China’s Tujia ethnic group, dihydromyricetin (DMY) is essentially a flavonoid. Its primary botanical source is the leaf of Ampelopsis grossedentata, a plant commonly known as “vine tea” or “Tujia divine tea” in the Hunan and Guangxi regions.
Locals have long steeped vine tea in water, using it mainly to clear heat, detoxify the body, and soothe throat discomfort. Systematic scientific research on vine tea began in China in the 1990s, and the range of activities examined in published studies gradually proved far broader than anyone expected.
This background is crucial: when an ingredient carries a long history of folk use, it often implies a relatively robust set of safety data, which can widen the path for subsequent development. That is a key reason why vine tea was approved as a New Food Ingredient in China in 2013, opening the door for its application in the food and dietary supplement sectors.
Hepatic Research — The Most-Studied Direction
As the dominant active constituent in vine tea, dihydromyricetin has been studied in published research for antioxidant, anti-inflammatory, alcohol-metabolism and hepatic endpoints. The volume of literature has been growing steadily. From a market-positioning standpoint, the hepatic/alcohol-metabolism area is where the research base and downstream interest are currently most concentrated.
There is an interesting mechanistic story here. Dihydromyricetin first caught the industry’s attention because of its regulatory effect on aldehyde dehydrogenase (ALDH). Acetaldehyde is the most toxic intermediate produced during alcohol metabolism; the ease with which it is converted to acetic acid directly determines how miserable one feels after drinking. Some animal studies suggest DMY can accelerate this conversion and reduce the malaise caused by acetaldehyde accumulation.
A 2025 study published in Food Research International by Zhejiang Chinese Medical University showed that the flavonoids in vine tea, led by dihydromyricetin, protect the liver through a multi-step process: inhibiting YTHDF2 → restoring PGC-1α/SIRT3 → safeguarding mitochondria → mitigating oxidative stress and inflammation. Significantly, this was the first time that m6A epigenetic regulation was linked to the hepatic activity of vine tea in this model, opening a new direction for further research.
I must add a crucial caveat, however: such research is predominantly preclinical (cell-based and small-animal models). High-quality randomized controlled trials in humans are still limited. Some product claims in the market – such as “rapid sobriety” or “drink all you want” – reach well beyond the current evidence. To put it responsibly: dihydromyricetin has a scientific foundation in the hangover-and-liver-protection space, but it is not yet at the stage where exaggerated promises can be made.
Beyond the hangover scenario, DMY’s protective effect against chemical liver injury also warrants attention. Alcohol-related and non-alcoholic fatty-liver models are among the more frequently reported research directions (research observations, not product or treatment claims), supported by in vitro and animal data. Research teams in China and abroad are also studying DMY’s effect on liver-fibrosis markers in such models — an area of ongoing academic interest rather than an established application.
Carbohydrate-Metabolism Research — Somewhat Underestimated
As research advances, published studies increasingly examine DMY’s activity related to carbohydrate metabolism. In animal models, DMY has shown α-glucosidase inhibitory activity, and some preclinical studies have investigated its interaction with the AMPK pathway, a node in glucose metabolism. These observations come from in vitro and animal research and are not product claims.
As market and regulatory context: in China, health foods containing DMY have already obtained registration under the approved "auxiliary blood-sugar-lowering" function category, though consumer awareness remains low. By contrast, the Japanese market has shown greater interest in this direction, with DMY already appearing in certain functional foods and dietary supplements positioned around carbohydrate-metabolism research.
Cellular-Senescence Research — A New Frontier
A research team including scientists from Shanghai Jiao Tong University School of Medicine published an article in Nature Communications titled “The natural flavonoid dihydromyricetin targets senescent cells via PRDX2 and alleviates age-related diseases” (March 6, 2026). The study used a natural product library screen and identified dihydromyricetin as possessing significant anti-aging activity. The researchers first screened a library of natural compounds and pinpointed several candidate phytochemicals, including DMY, with potential senolytic activity. Further investigation demonstrated that DMY protects senescent fibroblasts from additional DNA damage and attenuates the senescence-associated secretory phenotype (SASP), thereby exerting an anti-aging effect.
Why Hasn’t It Truly Taken Off?
After all these years, why is this ingredient still stuck in a perpetual “on the verge of exploding” state?
In my view, several factors are at play.
First, a hard flaw on the supply side. Although DMY can be extracted from vine tea, its natural content is not exceptionally high, and extraction costs have long been a barrier to large-scale application. Synthetic biology approaches are being explored, but we have yet to see a truly mature industrialization solution.
Second, too many functional directions without a concentrated focal point. Hangover relief, liver protection, blood sugar reduction, antioxidation – while many B2B companies effectively equate DMY with hangover-liver-care, it lacks the commanding presence of silymarin. From the C-end consumer perspective, no clear, strong association like “DMY = X” has been formed. Compare ergothioneine = anti-aging, PQQ = mitochondrial energy; the cognitive anchor is very explicit.
Third, fragmented brand recognition at the raw material level. There are numerous DMY extraction enterprises in China, but few have built a distinct brand name and a complete go-to-market strategy comparable to what Bloomage Biotech has done for ergothioneine. Brand building for this category at the B2B level is still in its infancy.
Where is the Next Window of Opportunity?
If I were to identify the signals that will herald DMY’s true breakout, I’d watch for the following:
-
Updates in New Food Ingredient approvals. Recent developments in China’s New Food Ingredient dossiers show that vine tea polyphenols have been submitted for approval. Dihydromyricetin is a key component of vine tea polyphenols. This sends a positive signal: if vine tea polyphenols are approved as a New Food Ingredient, opening up applications in general food categories, downstream brands’ willingness to develop products will rise markedly, and DMY could ride that wave.
-
The entry of a major brand. An ingredient’s rise to fame sometimes hinges not on the raw material suppliers but on whether a sufficiently large brand turns it into a blockbuster product. Just as erythritol was popularized by Genki Forest in the early days, the functional beverage direction may be the most promising entry point for dihydromyricetin. The scenario of hangover-liver protection is real, and the competition within this niche is far less intense than in the anti-aging space.
-
Advances in synthetic biology. If a breakthrough in extraction cost reduction occurs in the next few years, the entire business logic will undergo a fundamental shift. That said, naturally sourced dihydromyricetin will still retain its own advantages.
Final Thoughts
Writing this piece leaves me with a certain wistfulness: dihydromyricetin is an ingredient with history, data, and potential, yet its industrialization and market recognition in China lag far behind its research fervor.
What it needs is not more papers, but a player who truly understands the market and is willing to invest boldly.
Perhaps, when the next wave arrives, it won’t be left behind again.
What This Means for Buyers
For B2B buyers evaluating dihydromyricetin as a bulk ingredient, three points matter:
- Supply and cost. Confirm the botanical source (vine tea, Ampelopsis grossedentata), assay/standardization and extraction route; natural DMY content is limited, so capacity and cost vary by supplier.
- Specification and documentation. Request a batch-specific COA and TDS, and confirm assay method (typically HPLC), heavy metals, residual solvents and microbial limits.
- Market-specific regulation. Permitted use and any functional registration differ between China and overseas markets; confirm the regulatory status for your target market before committing volume.
GreeneryBio supplies dihydromyricetin with batch documentation (COA, TDS, MSDS available on request). For specification, pricing, or samples, contact our team.
This article is provided for B2B ingredient evaluation only. It summarizes published research and market context and is not a drug, health, disease or treatment claim. Confirm the regulatory status of any ingredient and claim in your target market before use.
References
Vine tea (Ampelopsis grossedentata) ameliorates chronic alcohol-induced hepatic steatosis, oxidative stress, and inflammation via YTHDF2/PGC-1α/SIRT3 axis, Food Research International, 2025, Zhejiang Chinese Medical University.
The natural flavonoid dihydromyricetin targets senescent cells via PRDX2 and alleviates age-related diseases, Nature Communications, 2026-03-06, Shanghai Jiao Tong University School of Medicine.
Huang XQ, Zhang DD, Chen M, Zhang SN. Research progress of dihydromyricetin in the treatment of diabetes and its complications. Journal of Hubei University of Science and Technology (Medical Sciences), 2025, 39(5):456-460.